Driven by a passion for pioneering science and a deep-seated commitment to human health, we are focused on delivering revolutionary treatments for cardiometabolic disease. Radella’s platform enables our therapies to avoid the off-target effects commonly associated with previous attempts to drug the target protein, while retaining strong selectivity and specificity.

 

• Attenuates expression of target protein by blocking a specific protein-protein interaction 

• Protein-protein interaction is shown to have an effect on insulin sensitivity and energy expenditure

• Critical pathway in multiple diseases, including diabetes, obesity, atherosclerosis, and liver disease

 

 

In relevant nonclinical models to date, we have observed results that support initiating human clinical trials, which are planned to start in early 2024.

​

• Increased insulin sensitivity

• Reduction in weight gain

• Preservation of lean mass

• Safe and well-tolerated